

**NEOSTIM** IS A SINGLE LAYER AMNION DERIVED ALLOGRAFT OPTIMIZED FOR WOUND COVERING, AND PROTECTION.

### THE NEOSTIM ADVANTAGE

Provides a reliable protective wound covering • 5-year shelf life at ambient temperature storage

Adheres easily to wounds including those with irregular surfaces\*

· Dehydrated extracellular matrix acts as a scaffold supporting the native tissue

# ORDERING INFORMATION (Q4266)

	l sates	
Product #	Size	Total Units (Per Sqcm)
NSM-020202	2x2	4
NSM-020203	2x3	6
NSM-020404	4x4	16
NSM-020406	4x6	24
NSM-020408	4x8	32
NSM-021016	10x16	160

NeoStim is an amniotic membrane allograft derived from a prescreened mother with a planned C-section delivery. NeoStim is manufactured in compliance with FDA regulations. The membrane is minimally processed to preserve the native structure of the tissue, dehydrated, and terminally sterilized. NeoStim is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.

\*Standard fixation techniques can be utilized with the allograft. Refer to the instructions for use.

VISIT OUR WEBSITE





## Why Amniotic Membrane?

Human amniotic membrane forms the innermost layer of placenta tissue. The avascular membrane acts as a protective barrier for the developing fetus. Its properties provide a wide variety of potential benefits.

#### **Protective Covering**

The membrane sheet provides a protective covering that may aid in wound management


#### **Growth Factors**

The membrane is a natural source of cytokines and growth factors<sup>3</sup>

### Why NeoStim?

NeoStim has been shown to be effective as a protective covering in the management of chronic non-healing foot ulcers including diabetic, pressure, and venous ulcers.

In a 10 patient case series, 95% of wound closure was acheived after 8 weeks of treatment in patients who previously failed standard of care.



# **NeoStim Allografts**

The NeoStim family of allografts are dehydrated, terminally irradiated membranes. The allograft family is available in multiple configurations and sizes to accommodate a variety of physician preferences.

NeoStim is regulated under Section 361 of the Public Health Service Act and is intended for homologous use.

### **Acesso Quality**

The NeoStim family of allografts are processed in compliance with all current Good Tissue Practices as mandated by the United States Food and Drug Administration. We pride ourselves on quality standards and testing that meet or exceed industry standards.

### **Our Process**

